NEW YORK, Jan 8 – Gene Logic has signed on IDEC pharmaceuticals, a developer of antibody therapeutics, as a multi-year subscriber to its GeneExpress Oncology DataSuite, Gene Logic announced Monday.
IDEC will use the database to discover and develop cancer therapeutics. The database provides disease-specific gene expression profiles for a number of human cancer types . The system will be deployed, along with Gene Logic’s GX2000 software, throughout the company’s R&D unit.
Financial terms of the subscription agreement were not disclosed.
“We are very pleased to establish a partnership with IDEC Pharmaceuticals to support their focused research on cancer," Gene Logic CEO Mark Gessler said in a statement. " This partnership strengthens and further validates our ongoing strategy of delivering targeted solutions that address the specialized needs of our pharmaceutical and biotechnology customers as they pursue genomics-driven drug development initiatives."
Gene Logic has recently signed as subscribers to its databases Organon, Boehringer Ingelheim Pharmaceuticals, Biogen, Proctor & Gamble,